Shanta Chawla

Internal Medicine

Irvine, CA 92602

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 4 publications

Safety and efficacy of same-day administration of eflapegrastim in patients with early-stage breast cancer receiving chemotherapy.

Safety and efficacy of same-day administration of eflapegrastim in patients with early-stage breast cancer receiving chemotherapy.

Journal: The oncologist

Published: April 15, 2025

Justification for a Fixed Dose of Eflapegrastim, a Long-Acting G-CSF, in Patients Receiving Docetaxel-Cyclophosphamide Chemotherapy.

Justification for a Fixed Dose of Eflapegrastim, a Long-Acting G-CSF, in Patients Receiving Docetaxel-Cyclophosphamide Chemotherapy.

Journal: Journal of clinical pharmacology

Published: May 15, 2020

A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study.

A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study.

Journal: Cancer medicine

Published: March 25, 2020

Eflapegrastim, a Long-Acting Granulocyte-Colony Stimulating Factor for the Management of Chemotherapy-Induced Neutropenia: Results of a Phase III Trial.

Eflapegrastim, a Long-Acting Granulocyte-Colony Stimulating Factor for the Management of Chemotherapy-Induced Neutropenia: Results of a Phase III Trial.

Journal: The oncologist

Published: February 10, 2020

Showing 1-4 of 4

Last Updated: 09/26/2026